Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Tafasitab 与 α1T 细胞或同种异体 NK 细胞疗法联合使用，可杀伤 B 细胞非霍奇金淋巴瘤
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-022-03165-w
Her Jung Hyun, Pretscher Dominik, Patra-Kneuer Maria, Schanzer Juergen, Cho Sung Yoo, Hwang Yu Kyeong, Hoeres Timm, Boxhammer Rainer, Heitmueller Christina, Wilhelm Martin, Steidl Stefan, Endell Jan
